THG 113
Alternative Names: PDC-31; PDC-41; PHG 113; THG113.31Latest Information Update: 14 Mar 2016
At a glance
- Originator Theratechnologies
- Developer PDC Biotech
- Class Peptides
- Mechanism of Action Prostaglandin F2 alpha antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dysmenorrhoea; Preterm labour
Most Recent Events
- 10 Dec 2012 PDC Biotech completes a phase I trial in Dysmenorrhoea in Austria and Germany (NCT01250587)
- 24 Jan 2012 Phase-I development is ongoing in Austria and Germany
- 12 May 2008 THG 113 licensed to PDC Biotech worldwide for the treatment of Dysmenorrhoea and prevention of Preterm labour